OKYO Pharma announces CEO presentation at Eyecelerator and CSO poster presentation at ARVO Annual Meeting on recent Phase 2 trial results for Urcosimod in neuropathic corneal pain.
Key takeaways
Robert J. Dempsey, CEO, presents at Eyecelerator on May 1, 2026, in Denver on unmet needs in corneal diseases.
Raj Patil, PhD, CSO, presents poster at ARVO on May 5, 2026, on first-in-human Urcosimod study showing pain reduction and quality-of-life improvement in NCP patients.
Urcosimod received FDA Fast Track designation and first IND for NCP treatment.
OKYO plans 150-patient Phase 2b/3 study of Urcosimod for NCP in first half of 2026.
Recent Phase 2 trial of Urcosimod in 18 NCP patients showed positive pain reduction data.